お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:ELOTUZUMAB(エロツズマブ):新たな洞察と市場予測(2030年)
市場調査レポート
商品コード
974761

ELOTUZUMAB(エロツズマブ):新たな洞察と市場予測(2030年)

ELOTUZUMAB- Emerging Insight and Market Forecast - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 60 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.72円
ELOTUZUMAB(エロツズマブ):新たな洞察と市場予測(2030年)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、主要7ヶ国市場(米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、および日本)におけるELOTUZUMAB(エロツズマブ)市場について調査しており、市場規模や2030年までの販売予測、製品概要、規制のマイルストーンやその他の開発活動、米国、欧州、日本全体の医薬品の研究開発活動、ELOTUZUMAB周辺の有効期限のタイムラインなどの特許情報、臨床試験情報などを掲載しています。

目次

第1章 薬剤の概要

  • 製品の詳細
  • 作用機序
  • 投薬と管理
  • 研究開発活動
    • 臨床開発
    • 安全性と有効性
  • その他の開発活動

第2章 市場評価

  • 主要7ヶ国市場分析
  • 米国市場
  • ドイツ市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 英国市場
  • 日本市場

第3章 SWOT分析

第4章 アナリストの見解

第5章 市場の競争

第6章 その他の新しい治療法

第7章 付録

第8章 購入オプションのレポート

図表

List of Tables

  • Table 1 ELOTUZUMAB, Description
  • Table 2 ELOTUZUMAB, Clinical Trial Description
  • Table 3 ELOTUZUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of ELOTUZUMAB
  • Figure 2 Patent Details, ELOTUZUMAB
  • Figure 3 ELOTUZUMAB, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 ELOTUZUMAB, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 ELOTUZUMAB, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 ELOTUZUMAB, Japan Market Size from 2020 to 2030 (in Millions USD)
目次
Product Code: DIDM0142

"ELOTUZUMAB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for AL Amyloidosis in 7 Major Markets. A detailed picture of the ELOTUZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Elotuzumab (brand name Empliciti, (Bristol-Myers Squibb and AbbVie), previously known as HuLuc63) is a humanized monoclonal antibody used in relapsed multiple myeloma. The package insert denotes its mechanism as a SLAMF7-directed (also known as CD 319) immunostimulatory antibody.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around ELOTUZUMAB.
  • The report contains forecasted sales for ELOTUZUMAB till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for AL Amyloidosis.
  • The report also features the SWOT analysis with analyst insights and key findings of ELOTUZUMAB.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ELOTUZUMAB Analytical Perspective by DelveInsight

  • In-depth ELOTUZUMAB Market Assessment

This report provides a detailed market assessment of ELOTUZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • ELOTUZUMAB Clinical Assessment

The report provides the clinical trials information of ELOTUZUMAB covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for AL Amyloidosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence ELOTUZUMAB dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for AL Amyloidosis are giving market competition to ELOTUZUMAB and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ELOTUZUMAB.
  • Our in-depth analysis of the forecasted sales data of ELOTUZUMAB from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ELOTUZUMAB.

Key Questions:

  • Which company is developing ELOTUZUMAB along with the phase of the clinical study?
  • What is the technology utilized in the development of ELOTUZUMAB?
  • What is the product type, route of administration and mechanism of action of ELOTUZUMAB?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ELOTUZUMAB development?
  • What are the key designations that have been granted to ELOTUZUMAB?
  • What is the forecasted market scenario of ELOTUZUMAB?
  • What is the history of ELOTUZUMAB and what is its future?
  • What is the forecasted sales of ELOTUZUMAB in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to ELOTUZUMAB?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.